Interstitial Lung Disease (ILD): In the PHAROS trial, 1 patient (1%) receiving MEKTOVI with BRAFTOVI developed pneumonitis. Assess new or progressive unexplained pulmonary symptoms or findings for ...
Overall survival (OS) data, published simultaneously by the Journal of Clinical Oncology, 2 show the longest survival data ...
Pivotal results from the Phase 3 BREAKWATER trial showed 51% risk reduction in death compared to standard-of-care treatment BRAFTOVI combination regimen also demonstrated 47% risk reduction in disease ...
Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and mFOLFOX6 ...
Using AI, we identified publications that likely reported a testing or mutation rate, filtered publications for cancer type, and identified sentences that likely reported rates. Rates and covariates ...
(RTTNews) - Pfizer Inc. (PFE) announced longer-term follow-up results from the Phase 2 single-arm PHAROS clinical trial evaluating the efficacy and safety of BRAFTOVI (encorafenib) in combination with ...
Phase III trial results supported recent FDA approval for patients with BRAF V600E mutations Data from this multi-institutional collaboration across 28 countries supported the accelerated approval of ...
BRAF V600E-mutant metastatic CRC is associated with poor clinical outcomes, with a median overall survival of 17 months. Factors influencing overall survival include metastasectomy and ECOG ...
Pfizer isn’t stopping to smell the roses on its speed run to secure a full FDA approval for its Braftovi combination therapy. After securing a unique accelerated approval not quite six months ago, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback